Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Fig. 3

Forest plot of hazard ratio of risk of new-onset AF for DM patients treated with metformin plus DPP-4 inhibitor versus other hypoglycemic agents after propensity score weighting. DPP4i is shown to be associated with a lower risk of new-onset AF compared with other hypoglycemic agents in most subgroups. DPP4i dipeptidyl peptidase-4 inhibitor

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840